In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Wilex licenses Centocor's G250 cancer mAb

Executive Summary

Munich-based cancer therapeutics start-up Wilex Biotechnology GMBH has licensed exclusive worldwide rights to Centocor's Phase I G250 monoclonal antibody to determine its therapeutic potential in renal cancer applications. Centocor has the option to market the product in the US, upon which it will pay Wilex an up-front payment in addition to milestones and profits on sales.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies